Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03882918 · ClinicalTrials.gov registry record · Phase 3
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
A Phase 3 study, sponsored by Healx AI.
- Terminated
- Registry status
- Phase 3
- Development phase
- 141
- Enrollment target
NCT03882918 is a Phase 3 study that was terminated before completion, run by Healx AI. The registered enrollment target is 141 participants.
The verdict
NCT03882918, a Phase 3 study, was terminated before completion, sponsored by Healx AI.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 141 participants
- Enrollment target
Study Summary
This open-label study (OV101-18-002) will evaluate the long-term (52 weeks) safety of OV101 in subjects with AS and provide additional OV101 treatment to those subjects who completed Study OV101-15-001 (NCT02996305). Subjects with AS who completed the pharmacokinetic Study OV101-16-001 (NCT03109756) will also be permitted to participate, provided they meet all entry criteria.
Interventions
- DRUG OV101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2019-01-31 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03882918
The ClinicalTrials.gov registry entry for NCT03882918 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Healx AI, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OV101 is the first listed.
NCT03882918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03882918 about?
NCT03882918 is a clinical study titled "An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome". This open-label study (OV101-18-002) will evaluate the long-term (52 weeks) safety of OV101 in subjects with AS and provide additional OV101 treatment to those subjects who completed Study OV101-15-001 (NCT02996305). Subjects with AS who completed the pharmacokinetic Study OV101-16-001 (NCT03109756)...
What is the current status of trial NCT03882918?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 141 participants. The study started on 2019-01-31. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT03882918?
The interventions under investigation include: OV101 (DRUG).
Who is sponsoring clinical trial NCT03882918?
This trial is sponsored by Healx AI, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.